These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 34595951)

  • 21. A bitter pill: formulary variability and the challenge to prescribing physicians.
    Shrank WH; Ettner SL; Glassman P; Asch SM
    J Am Board Fam Pract; 2004; 17(6):401-7. PubMed ID: 15575031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How do incentive-based formularies influence drug selection and spending for hypertension?
    Kamal-Bahl S; Briesacher B
    Health Aff (Millwood); 2004; 23(1):227-36. PubMed ID: 15002647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018-2020.
    Khazanchi R; Powers S; Killelea A; Strumpf A; Horn T; Hamp A; McManus KA
    J Pharm Policy Pract; 2023 Apr; 16(1):57. PubMed ID: 37081570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of cost sharing in the Pima County Marketplace.
    Jennings NB; Eng HJ
    Health Policy; 2017 Jan; 121(1):50-57. PubMed ID: 27916433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Specialty Medication Use for Common Chronic Inflammatory Diseases Among Health Exchange and Other Commercially Insured Members.
    Chen X; Gautam S; Ruggieri A; Richards T; Devries A; Sylwestrzak G
    J Manag Care Spec Pharm; 2018 Jan; 24(1):12-19. PubMed ID: 29290173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3-tier drug benefit designs based on sound drug formulary principles will maximize favorable outcomes.
    Curtiss FR
    J Manag Care Pharm; 2004; 10(1):83-4, 86. PubMed ID: 14720109
    [No Abstract]   [Full Text] [Related]  

  • 30. Constraints on Formulary Design Under the Affordable Care Act.
    Andersen M
    Health Econ; 2017 Dec; 26(12):e160-e178. PubMed ID: 28233420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complying with state and federal regulations on essential drug benefits: implementing the Affordable Care Act.
    Cohen JP; Felix A; Vasiadi M
    Am J Manag Care; 2014 Feb; 20(2):153-8. PubMed ID: 24738533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three years in - changing plan features in the U.S. health insurance marketplace.
    McKillop CN; Waters TM; Kaplan CM; Kaplan EK; Thompson MP; Graetz I
    BMC Health Serv Res; 2018 Jun; 18(1):450. PubMed ID: 29902996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs.
    Nemlekar P; Shepherd M; Lawson K; Rush S
    J Manag Care Pharm; 2013 Oct; 19(8):602-8. PubMed ID: 24074006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit.
    Spence MM; Hui R; Chan J
    J Manag Care Pharm; 2006 Jun; 12(5):377-82. PubMed ID: 16792444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs.
    Dusetzina SB; Cubanski J; Roberts AW; Hoadley J; True S; Nshuti L; Neuman T
    Am J Manag Care; 2021 Jul; 27(7):283-288. PubMed ID: 34314117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.
    Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS
    Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Second Year Of Marketplaces, New Entrants, ACA 'Co-Ops,' And Medicaid Plans Restrain Average Premium Growth Rates.
    Gabel JR; Whitmore H; Green M; Stromberg ST; Weinstein DS; Oran R
    Health Aff (Millwood); 2015 Dec; 34(12):2020-6. PubMed ID: 26643621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.